非酒精性脂肪性肝炎与肠道微生物群：对新疗法的启示
NASH and the Gut Microbiome: Implications for New Therapies.
作者信息
Tsay Cynthia J, Lim Joseph K
机构信息
Department of Internal Medicine Yale University New Haven CT.
Yale Liver Center and Section of Digestive Diseases Yale University New Haven CT.
出版信息
Clin Liver Dis (Hoboken). 2022 Jan 28;19(3):97-100. doi: 10.1002/cld.1170. eCollection 2022 Mar.
Abstract
Content available: Author Audio Recording.
摘要
内容提供
作者音频记录。
相似文献
1
NASH and the Gut Microbiome: Implications for New Therapies.
Clin Liver Dis (Hoboken). 2022 Jan 28;19(3):97-100. doi: 10.1002/cld.1170. eCollection 2022 Mar.
2
Modeling dysbiosis of human NASH in mice: Loss of gut microbiome diversity and overgrowth of Erysipelotrichales.
PLoS One. 2021 Jan 4;16(1):e0244763. doi: 10.1371/journal.pone.0244763. eCollection 2021.
3
Diet and gut microbiome in fatty liver and its associated liver cancer.
J Gastroenterol Hepatol. 2022 Jan;37(1):7-14. doi: 10.1111/jgh.15713. Epub 2021 Nov 3.
4
Non-alcoholic fatty liver and the gut microbiota.
Mol Metab. 2016 Jun 14;5(9):782-94. doi: 10.1016/j.molmet.2016.06.003. eCollection 2016 Sep.
5
Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: A prospective pilot study.
Nutr Metab Cardiovasc Dis. 2018 Apr;28(4):369-384. doi: 10.1016/j.numecd.2017.10.014. Epub 2017 Oct 26.
6
Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis.
Eur J Nutr. 2018 Apr;57(3):861-876. doi: 10.1007/s00394-017-1524-x. Epub 2017 Sep 5.
7
Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
Biomolecules. 2021 Dec 31;12(1):56. doi: 10.3390/biom12010056.
8
Gut microbiome and nonalcoholic fatty liver diseases.
Pediatr Res. 2015 Jan;77(1-2):245-51. doi: 10.1038/pr.2014.157. Epub 2014 Oct 13.
9
Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications.
Aliment Pharmacol Ther. 2019 Jul;50(2):144-158. doi: 10.1111/apt.15314. Epub 2019 May 31.
10
Epidemiological and Genetic Aspects of NAFLD and NASH in Mexico.
Clin Liver Dis (Hoboken). 2022 Mar 10;19(2):68-72. doi: 10.1002/cld.1167. eCollection 2022 Feb.
引用本文的文献
1
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes.
Front Med (Lausanne). 2025 Aug 14;12:1618275. doi: 10.3389/fmed.2025.1618275. eCollection 2025.
2
Ruminococcus gnavus in the gut: driver, contributor, or innocent bystander in steatotic liver disease?
FEBS J. 2025 Mar;292(6):1252-1264. doi: 10.1111/febs.17327. Epub 2024 Nov 26.
3
A Scoping Review on Hepatoprotective Mechanism of Herbal Preparations through Gut Microbiota Modulation.
Curr Issues Mol Biol. 2024 Oct 16;46(10):11460-11502. doi: 10.3390/cimb46100682.
4
Emerging Therapies for Non-Alcoholic Steatohepatitis (NASH): A Comprehensive Review of Pharmacological and Non-Pharmacological Approaches.
Cureus. 2024 Sep 10;16(9):e69129. doi: 10.7759/cureus.69129. eCollection 2024 Sep.
5
Development of non-alcoholic steatohepatitis is associated with gut microbiota but not with oxysterol enzymes CH25H, EBI2, or CYP7B1 in mice.
BMC Microbiol. 2024 Feb 28;24(1):69. doi: 10.1186/s12866-024-03195-7.
6
The Role of in Liver Diseases: A Systematic Review of Next-Generation Sequencing Studies.
Microorganisms. 2023 Dec 17;11(12):2999. doi: 10.3390/microorganisms11122999.
7
Gut Microbiome in the Progression of NAFLD, NASH and Cirrhosis, and Its Connection with Biotics: A Bibliometric Study Using Dimensions Scientific Research Database.
Biology (Basel). 2023 Apr 27;12(5):662. doi: 10.3390/biology12050662.
8
Excessive gluconeogenesis causes the hepatic insulin resistance paradox and its sequelae.
Heliyon. 2022 Dec 15;8(12):e12294. doi: 10.1016/j.heliyon.2022.e12294. eCollection 2022 Dec.
9
Clearing Steatosis Prior to Liver Surgery for Colorectal Metastasis: A Narrative Review and Case Illustration.
Nutrients. 2022 Dec 15;14(24):5340. doi: 10.3390/nu14245340.
本文引用的文献
1
An update on the role of the microbiome in non-alcoholic fatty liver disease pathogenesis, diagnosis, and treatment.
Curr Treat Options Gastroenterol. 2020 Jun;18(2):270-280. doi: 10.1007/s11938-020-00290-2. Epub 2020 May 2.
2
The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies.
Nutrients. 2019 Nov 4;11(11):2642. doi: 10.3390/nu11112642.
3
Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications.
Aliment Pharmacol Ther. 2019 Jul;50(2):144-158. doi: 10.1111/apt.15314. Epub 2019 May 31.
4
Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
Expert Rev Gastroenterol Hepatol. 2019 Mar;13(3):193-204. doi: 10.1080/17474124.2019.1569513. Epub 2019 Jan 25.
5
The Intestinal Microbiome, Plasma Metabolome, and Liver Transcriptome: A Conspiracy Driving Hepatic Steatosis.
Hepatology. 2019 Aug;70(2):741-744. doi: 10.1002/hep.30577. Epub 2019 Apr 11.
6
The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD).
Cell Mol Life Sci. 2019 Apr;76(8):1541-1558. doi: 10.1007/s00018-019-03011-w. Epub 2019 Jan 25.
7
The role of the microbiome in NAFLD and NASH.
EMBO Mol Med. 2019 Feb;11(2). doi: 10.15252/emmm.201809302.
8
Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function.
Clin Gastroenterol Hepatol. 2019 Jan;17(2):296-306. doi: 10.1016/j.cgh.2018.08.065. Epub 2018 Sep 7.
9
Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy.
Nutrients. 2017 Oct 16;9(10):1124. doi: 10.3390/nu9101124.
10
Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition.
Cell Metab. 2017 Oct 3;26(4):611-619.e6. doi: 10.1016/j.cmet.2017.09.008.
Zotero 插件